G1 Therapeutics Valuation
| GTHXDelisted Stock | USD 7.15 0.00 0.00% |
At this time, the entity appears to be overvalued. G1 Therapeutics owns a latest Real Value of $5.03 per share. The recent price of the entity is $7.15. Our model calculates the value of G1 Therapeutics from inspecting the entity fundamentals such as Shares Owned By Insiders of 10.92 %, operating margin of (0.21) %, and Return On Asset of -0.19 as well as reviewing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that G1 Therapeutics' price fluctuation is very steady at this time. Calculation of the real value of G1 Therapeutics is based on 3 months time horizon. Increasing G1 Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since G1 Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of GTHX Stock. However, G1 Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 7.15 | Real 5.03 | Hype 7.15 | Naive 7.64 |
The intrinsic value of G1 Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence G1 Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of G1 Therapeutics helps investors to forecast how GTHX stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of G1 Therapeutics more accurately as focusing exclusively on G1 Therapeutics' fundamentals will not take into account other important factors: G1 Therapeutics Total Value Analysis
G1 Therapeutics is currently forecasted to have valuation of 364.46 M with market capitalization of 377.22 M, debt of 57.17 M, and cash on hands of 143.96 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the G1 Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
364.46 M | 377.22 M | 57.17 M | 143.96 M |
G1 Therapeutics Investor Information
About 55.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 0.86. G1 Therapeutics had not issued any dividends in recent years. Based on the key indicators related to G1 Therapeutics' liquidity, profitability, solvency, and operating efficiencyBased on the analysis of, G1 Therapeutics is not in a good financial situation at the moment. It has a very high risk of going through financial straits in January.G1 Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. G1 Therapeutics has an asset utilization ratio of 67.89 percent. This suggests that the Company is making $0.68 for each dollar of assets. An increasing asset utilization means that G1 Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.G1 Therapeutics Ownership Allocation
G1 Therapeutics secures a total of 52.76 Million outstanding shares. Over half of G1 Therapeutics' outstanding shares are owned by institutions. These institutions are typically referred to as corporate investors that purchase positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company retains, if the real value of the entity is less than the current market value, you may not be able to make money on it.G1 Therapeutics Profitability Analysis
The company reported the previous year's revenue of 82.51 M. Net Loss for the year was (47.97 M) with profit before overhead, payroll, taxes, and interest of 47.55 M.About G1 Therapeutics Valuation
Our relative valuation model uses a comparative analysis of G1 Therapeutics. We calculate exposure to G1 Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of G1 Therapeutics's related companies.G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina. G1 Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 148 people.
G1 Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 51.7 M |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Other Consideration for investing in GTHX Stock
If you are still planning to invest in G1 Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the G1 Therapeutics' history and understand the potential risks before investing.
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |